CN113874350B - 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物 - Google Patents

作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物 Download PDF

Info

Publication number
CN113874350B
CN113874350B CN202080027716.4A CN202080027716A CN113874350B CN 113874350 B CN113874350 B CN 113874350B CN 202080027716 A CN202080027716 A CN 202080027716A CN 113874350 B CN113874350 B CN 113874350B
Authority
CN
China
Prior art keywords
compound
hydroxy
inden
fluoro
cyclopenta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080027716.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113874350A (zh
Inventor
傅继平
娄焱
何一刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Linkang Therapy Co
Original Assignee
Nican Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nican Therapy filed Critical Nican Therapy
Priority to CN202411099450.0A priority Critical patent/CN118993938A/zh
Priority to CN202411099453.4A priority patent/CN118993939A/zh
Publication of CN113874350A publication Critical patent/CN113874350A/zh
Application granted granted Critical
Publication of CN113874350B publication Critical patent/CN113874350B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/48—Halogenated derivatives
    • C07C35/52—Alcohols with a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/96—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members
    • C07C2603/97—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members containing five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080027716.4A 2019-04-18 2020-04-16 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物 Active CN113874350B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202411099450.0A CN118993938A (zh) 2019-04-18 2020-04-16 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物
CN202411099453.4A CN118993939A (zh) 2019-04-18 2020-04-16 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962836019P 2019-04-18 2019-04-18
US62/836019 2019-04-18
US201962946191P 2019-12-10 2019-12-10
US62/946191 2019-12-10
PCT/US2020/028579 WO2020214853A1 (en) 2019-04-18 2020-04-16 Tetrahydro-1h-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202411099453.4A Division CN118993939A (zh) 2019-04-18 2020-04-16 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物
CN202411099450.0A Division CN118993938A (zh) 2019-04-18 2020-04-16 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物

Publications (2)

Publication Number Publication Date
CN113874350A CN113874350A (zh) 2021-12-31
CN113874350B true CN113874350B (zh) 2024-08-06

Family

ID=71094790

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080027716.4A Active CN113874350B (zh) 2019-04-18 2020-04-16 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物
CN202411099453.4A Pending CN118993939A (zh) 2019-04-18 2020-04-16 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物
CN202411099450.0A Pending CN118993938A (zh) 2019-04-18 2020-04-16 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202411099453.4A Pending CN118993939A (zh) 2019-04-18 2020-04-16 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物
CN202411099450.0A Pending CN118993938A (zh) 2019-04-18 2020-04-16 作为缺氧可诱导因子-2(α)抑制剂的四氢-1H-环戊二烯并[CD]茚衍生物

Country Status (14)

Country Link
US (6) US20200361855A1 (cg-RX-API-DMAC7.html)
EP (1) EP3956299A1 (cg-RX-API-DMAC7.html)
JP (1) JP7581236B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210154191A (cg-RX-API-DMAC7.html)
CN (3) CN113874350B (cg-RX-API-DMAC7.html)
AU (1) AU2020260130C1 (cg-RX-API-DMAC7.html)
CA (1) CA3136650A1 (cg-RX-API-DMAC7.html)
IL (1) IL287258B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021012549A (cg-RX-API-DMAC7.html)
SG (1) SG11202111118YA (cg-RX-API-DMAC7.html)
TW (1) TWI871313B (cg-RX-API-DMAC7.html)
UA (1) UA128792C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020214853A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108270B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12171741B2 (en) 2018-09-11 2024-12-24 Nikang Therapeutics, Inc. 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
EP3866927A4 (en) 2018-10-17 2022-07-27 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
IL287258B2 (en) 2019-04-18 2026-01-01 Nikang Therapeutics Inc Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha
US20220274914A1 (en) * 2019-07-22 2022-09-01 Nikang Therapeutics, Inc. Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
US11420936B2 (en) 2020-04-16 2022-08-23 Nikang Therapeutics, Inc. Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases
CN115485262B (zh) * 2020-04-16 2025-04-04 霖康疗法公司 低氧诱导因子-2(α)抑制剂及其在疾病治疗中的用途
CN114315552B (zh) * 2020-09-30 2024-08-02 江西济民可信集团有限公司 三并环类化合物及其制备方法和应用
WO2022082337A1 (en) * 2020-10-19 2022-04-28 Nikang Therapeutics, Inc. Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile
WO2022082329A1 (en) * 2020-10-19 2022-04-28 Nikang Therapeutics, Inc. Processes of preparing 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile
WO2022086882A1 (en) 2020-10-21 2022-04-28 Nikang Therapeutics, Inc. Diagnostic and therapeutic methods for treatment of cancer with a hif-2(alpha) inhibitor
US20220251218A1 (en) * 2021-02-10 2022-08-11 Gnt Biotech & Medicals Corporation Pharmaceutical combination and method for overcoming immune suppression or stimulating immune response against cancer
IL305405A (en) * 2021-02-23 2023-10-01 Shanghai Jemincare Pharmaceuticals Co Ltd A tricyclic compound as a HIF2-alpha inhibitor, its preparation method and application
US12145901B1 (en) 2021-09-17 2024-11-19 Arcus Biosciences, Inc. Process for preparing tetralin compounds
WO2023060431A1 (en) 2021-10-12 2023-04-20 Nikang Therapeutics, Inc. Processes of making 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile and polymorphs thereof
TW202317074A (zh) 2021-10-12 2023-05-01 美商尼坎醫療公司 製備3-氟-5-(((1S,2aR)-1,3,3,4,4-五氟-2a-羥基-2,2a,3,4-四氫-1H-環戊二烯并[CD]茚-7-基)氧基)苄腈及其多晶型物之方法
CN116916900A (zh) * 2021-10-18 2023-10-20 尼坎治疗公司 用于治疗膀胱癌的低氧诱导因子-2(α)抑制剂
WO2023070483A1 (en) 2021-10-29 2023-05-04 Nikang Therapeutics, Inc. PROCESSES OF MAKING 3-FLUORO-5- ( ( (1R, 2S, 2aS) -1, 2, 3, 3, 4, 4-HEXAFLUORO-2A-HYDROXY-2, 2A, 3, 4-TETRAHYDRO-1H-CYCLOPENTA [CD] INDEN-7-YL) -OXY) -BENZONITRILE AND POLYMORPHS THEREOF
WO2024240240A1 (zh) * 2023-05-24 2024-11-28 江苏恩华药业股份有限公司 一种咪唑衍生物、中间体、制备方法及其应用
WO2025230942A1 (en) 2024-05-03 2025-11-06 Nikang Therapeutics, Inc. Pharmaceutical compositions of 3-fluoro-5-(((ls,2ar)-l,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile
WO2025231006A1 (en) 2024-05-03 2025-11-06 Nikang Therapeutics, Inc. Pharmaceutical compositions of 3-fluoro-5-(((1s,2ar)-1,3,3,4,4- pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h- cyclopenta[cd]inden-7-yl)oxy)-benzonitrile
WO2025235034A1 (en) * 2024-05-04 2025-11-13 Nikang Therapeutics, Inc. 3-fluoro-5-(((ls,2ar)-1,3,3,4, 4-pentafluoro-2a-hydroxy-2,2a, 3,4-tetrahydro-lh-cyclopenta[cd]inden-7- yl)oxy)- benzonitrile dosing regimen for use in the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105530923A (zh) * 2013-09-09 2016-04-27 佩洛通治疗公司 芳基醚及其用途
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133279A (en) 1996-06-26 2000-10-17 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for renal diseases and organ preservatives
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
CN103717214A (zh) 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
CA2842730C (en) 2011-07-22 2018-08-21 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
CA2931085C (en) 2013-12-16 2021-10-19 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
US10098878B2 (en) 2014-10-10 2018-10-16 The Board Of Regents Of The University Of Texas System HIF-2α inhibitors for treating iron overload disorders
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
EP3268362B1 (en) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
US20190048421A1 (en) 2015-09-21 2019-02-14 The Board Of Regents Of The University Of Texas System Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof
AU2018330994A1 (en) 2017-09-15 2020-04-16 GlaxoSmithKline Intellectual Property (No. 2) Limited, England Crystalline forms of gsk1278863, preparation method and pharmaceutical use thereof
TW202003430A (zh) 2018-03-28 2020-01-16 美商佩樂敦治療公司 以HIF-2-α之抑制劑降低消化系統發炎之方法
US12171741B2 (en) 2018-09-11 2024-12-24 Nikang Therapeutics, Inc. 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
EP3866927A4 (en) 2018-10-17 2022-07-27 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
IL287258B2 (en) 2019-04-18 2026-01-01 Nikang Therapeutics Inc Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha
US20220274914A1 (en) 2019-07-22 2022-09-01 Nikang Therapeutics, Inc. Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors
CN115485262B (zh) 2020-04-16 2025-04-04 霖康疗法公司 低氧诱导因子-2(α)抑制剂及其在疾病治疗中的用途
US11420936B2 (en) 2020-04-16 2022-08-23 Nikang Therapeutics, Inc. Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases
WO2022082337A1 (en) 2020-10-19 2022-04-28 Nikang Therapeutics, Inc. Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile
WO2022082329A1 (en) 2020-10-19 2022-04-28 Nikang Therapeutics, Inc. Processes of preparing 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile
TW202317074A (zh) 2021-10-12 2023-05-01 美商尼坎醫療公司 製備3-氟-5-(((1S,2aR)-1,3,3,4,4-五氟-2a-羥基-2,2a,3,4-四氫-1H-環戊二烯并[CD]茚-7-基)氧基)苄腈及其多晶型物之方法
CN116916900A (zh) 2021-10-18 2023-10-20 尼坎治疗公司 用于治疗膀胱癌的低氧诱导因子-2(α)抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105530923A (zh) * 2013-09-09 2016-04-27 佩洛通治疗公司 芳基醚及其用途
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation

Also Published As

Publication number Publication date
SG11202111118YA (en) 2021-11-29
US11267782B2 (en) 2022-03-08
US12391642B2 (en) 2025-08-19
US11753366B2 (en) 2023-09-12
AU2020260130A1 (en) 2021-11-04
US20210246102A1 (en) 2021-08-12
US20230373909A1 (en) 2023-11-23
JP7581236B2 (ja) 2024-11-12
IL287258A (en) 2021-12-01
UA128792C2 (uk) 2024-10-23
TW202104174A (zh) 2021-02-01
CN118993939A (zh) 2024-11-22
ZA202108270B (en) 2026-01-28
AU2020260130C1 (en) 2025-12-11
CN118993938A (zh) 2024-11-22
WO2020214853A1 (en) 2020-10-22
CA3136650A1 (en) 2020-10-22
US20250340508A1 (en) 2025-11-06
JP2022529166A (ja) 2022-06-17
CN113874350A (zh) 2021-12-31
US20210347729A1 (en) 2021-11-11
AU2020260130B2 (en) 2025-08-07
TWI871313B (zh) 2025-02-01
BR112021020637A2 (pt) 2022-02-15
IL287258B2 (en) 2026-01-01
EP3956299A1 (en) 2022-02-23
US20200361855A1 (en) 2020-11-19
KR20210154191A (ko) 2021-12-20
MX2021012549A (es) 2022-01-18
US20220162158A1 (en) 2022-05-26
IL287258B1 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
US12391642B2 (en) Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US12077506B2 (en) Indane derivatives as hypoxia inducible factor-2(α) inhibitors
CN115485262B (zh) 低氧诱导因子-2(α)抑制剂及其在疾病治疗中的用途
WO2021016280A1 (en) Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors
US12171741B2 (en) 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
TW202317074A (zh) 製備3-氟-5-(((1S,2aR)-1,3,3,4,4-五氟-2a-羥基-2,2a,3,4-四氫-1H-環戊二烯并[CD]茚-7-基)氧基)苄腈及其多晶型物之方法
WO2023060458A1 (en) Processes of making 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile and polymorphs thereof
US20220380302A1 (en) Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases
CN116916900A (zh) 用于治疗膀胱癌的低氧诱导因子-2(α)抑制剂
BR112021020637B1 (pt) Derivados de tetra-hidro-1h-ciclopenta[cd]indeno inibidores de fator -2(alfa) induzível por hipóxia, forma cristalina, composição e uso dos mesmos
EA049056B1 (ru) ПРОИЗВОДНЫЕ ТЕТРАГИДРО-1Н-ЦИКЛОПЕНТА[cd]ИНДЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА-2 (АЛЬФА), ИНДУЦИРУЕМОГО ГИПОКСИЕЙ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Delaware, USA

Patentee after: Linkang Therapy Co.

Country or region after: U.S.A.

Address before: Delaware, USA

Patentee before: Nican therapy

Country or region before: U.S.A.

CP03 Change of name, title or address